Trial Profile
The prospective, open-lable, single-arm, single-center clinical study of Apatinib mesylate non-first-line used in treating patients with recurrent/metastatic soft tissue sarcoma.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 14 Jul 2017 New trial record